bacteriostatic

(redirected from B. fragilis)
Also found in: Dictionary.
Related to B. fragilis: Bacillus fragilis, B. cereus

bacteriostatic

 [bak-te″re-o-stat´ik]
arresting the growth or multiplication of bacteria; also, an agent that so acts.

bac·te·ri·o·stat·ic

(bak-tēr'ē-ō-stat'ik),
Inhibiting or retarding the multiplication of bacteria.

bacteriostatic

adjective Referring to inhibition of bacterial growth and/or reproduction.
 
noun An agent which inhibits bacterial growth and/or reproduction.

bacteriostatic

Biology adjective Referring to inhibition of bacterial growth and/or reproduction noun An agent that inhibits bacterial growth and/or reproduction. Cf Bactericidal.

bac·te·ri·o·stat·ic

(bak-tēr'ē-ō-stat'ik)
Inhibiting or retarding the growth of bacteria.

bacteriostatic

Able to restrain or control the multiplication of bacteria, without actually killing them. When a bacteriostatic effect is achieved organisms are more susceptible to destruction by the immune system.

bacteristatic

or

bacteriostatic

capable of inhibiting the growth of BACTERIA, but not of killing them. Compare BACTERICIDAL.

bacteriostatic 

A term describing substances such as sulfonamides and tetracycline which inhibit the growth and propagation of bacteria, but do not actually destroy bacteria. See antibiotic.

bac·te·ri·o·stat·ic

(bak-tēr'ē-ō-stat'ik)
Inhibiting or retarding the multiplication of bacteria.
References in periodicals archive ?
Initial comparison of the clinical isolate with the 3 completed B. fragilis reference genomes (638R, YCH46, NCTC 9343) showed a high degree of sequence divergence (Figure).
The clinical isolate contained an estimated 5.50 Mbp of DNA, [approximately equal to] 20% more than sequenced B. fragilis reference strains, and 43.81% GC content.
Both blood culture and abdominal fluid culture isolates were identified as B. fragilis. Both isolates demonstrated high levels of resistance by epsilometer test (E-test) to multiple antibiotics, including metronidazole, imipenem, piperacillin/ tazobactam, and clindamycin.
Los genes que codifican la fragilisina se encuentran en una region cromosomal de 6 kb denominada isla de patogenicidad de B. fragilis (IPBF) que comprende los loci para tres isotipos de la enterotoxina denominados bft-1, bft-2ybft-3 (17,18).
Moreover, B. fragilis predominantly colonizes the lower left colon (2).
Making fucose from the sugar mannose is common in bacteria, including B. fragilis. Mammalian cells, in contrast, convert fucose from their surroundings into a form called guanosine diphosphate-fucose (GDP-fucose), which they attach to their surface proteins.
The British investigators recently proposed that the genus Bacteroides be limited to those organisms now classified as B. fragilis group (B.
Although B. fragilis exhibits the broadest spectrum of recognized resistance to antimicrobial agents among anaerobes, the worldwide rate of metronidazole resistance remains low, [is less than] 5% (1,2).
Enterotoxigenic B. fragilis (ETBF) is an emerging enteric pathogen associated with diarrheal diseases in children, adults, and animals (4,7-9).
In 1998, fewer than 2% of all B. fragilis from 39 hospitals were resistant to metronidazole (MICs [is greater than] 8 mg/L), and the number of imipenem-resistant strains remained low.